exv10w1







	 	 	 	 	 



Exhibit 10.1




AMENDED AND RESTATED




INDEMNIFICATION AGREEMENT





     AMENDED AND RESTATED INDEMNIFICATION AGREEMENT (this “Agreement”) dated as of December ___,
2008 by and between Sucampo Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, and
                                        (“Indemnitee”):



     WHEREAS, competent persons are reluctant to serve a corporation as a director or in another
capacity unless they are provided with adequate protection through insurance or adequate
indemnification against inordinate risks of claims and actions against them arising out of their
service to and activities on behalf of corporations;



     WHEREAS, the Board of Directors of the Company has determined that the ability to attract and
retain such persons is in the best interests of the Company’s stockholders and that the Company
should act to assure such persons that there will be increased certainty of such protection in the
future; and



     WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate
itself to indemnify such persons to the fullest extent permitted by applicable law so that they
will serve or continue to serve the Company free from undue concern that they will not be so
indemnified;



     WHEREAS, Indemnitee is willing to serve, continue to serve and to take on additional service
for or on behalf of the Company on the condition that Indemnitee be so indemnified; and



     WHEREAS, Indemnitee has an existing Indemnification Agreement with the Company dated
                                        ,
200___ (the “Existing Agreement”) and the Indemnitee and the Company desire to
amend and restate the Existing Agreement in its entirety;



     NOW, THEREFORE, in consideration of the premises, the mutual agreements herein set forth below
and other good and valuable consideration, the receipt and adequacy of which are hereby
acknowledged, the parties agree to amend and restate the Existing Agreement in its entirety as
follows:



     1. Definitions. For purposes of this Agreement the following terms shall have the
meanings set forth below:




     (a) “Board” shall mean the Board of Directors of the Company.




     (b) “Change of Control” shall mean any of the following events:




     (i) Unless approved by the affirmative vote of at least two-thirds of those
members of the Board who are in office immediately prior to the event(s) and who are
not employees of the Company:



Sucampo Pharmaceuticals, Inc.

Outside Director Indemnification Letter




 









 






     (A) the merger or consolidation of the Company with, or the sale of all
or substantially all of the assets of the Company to, any person or entity
or group of associated persons or entities; or




     (B) the acquisition of direct or indirect beneficial ownership in the
aggregate of securities of the Company representing twenty percent (20%) or
more of the total combined voting power of the Company’s then issued and
outstanding securities by any person or entity, or group of associated
persons or entities acting in concert, not affiliated (within the meaning of
the Securities Act of 1933) with the Company as of the date of this
Agreement; or




     (C) approval by the stockholders of the Company of any plan or proposal
for the liquidation or dissolution of the Company; or




     (ii) A change in the composition of the Board at any time during any
consecutive 24-month period such that the “Continuing Directors” cease for any
reason to constitute at least a seventy percent (70%) majority of the Board. For
purposes of this clause (ii), “Continuing Directors” means those members of the
Board who either:




     (A) were members of the Board at the beginning of such consecutive
24-month period; or




     (B) were elected by, or on the nomination or recommendation of, at
least a two-thirds majority (consisting of at least five directors) of the
then-existing Board.




     (c) “Corporate Status” describes the status of a person who is or was a director,
officer, employee, agent or fiduciary of the Company or of any other corporation,
partnership, joint venture, trust, employee benefit plan or other enterprise which such
person is or was serving at the express written request of the Company.




     (d) “Disinterested Director” means a director of the Company who is not and was not a
party to the Proceeding in respect of which indemnification is sought by Indemnitee.




     (e) “Enterprise” shall mean the Company and any other corporation, partnership, joint
venture, trust, employee benefit plan or other enterprise of which Indemnitee is or was
serving at the express written request of the Company as a director, officer, employee,
agent or fiduciary.




     (f) “Expenses” shall include all reasonable attorneys’ fees, retainers, court costs,
transcript costs, fees of experts, witness fees, travel expenses, duplicating costs,
printing and binding costs, telephone charges, postage, delivery service fees, and all other
disbursements or expenses of the types customarily incurred in connection with



Sucampo Pharmaceuticals, Inc.

Outside Director Indemnification Agreement




2









 






prosecuting, defending, preparing to prosecute or defend, investigating, being or
preparing to be a witness in a Proceeding.




     (g) “Good Faith” shall mean Indemnitee having acted in good faith and in a manner
Indemnitee reasonably believed to be in or not opposed to the best interests of the Company,
and, with respect to any criminal Proceeding, having had no reasonable cause to believe
Indemnitee’s conduct was unlawful.




     (h) “Independent Counsel” means a law firm, or a member of a law firm, that is
experienced in matters of corporation law and neither presently is, nor in the past five
years has been, retained to represent: (i) the Company or Indemnitee in any matter material
to either such party or (ii) any other party to the Proceeding giving rise to a claim for
indemnification hereunder. Notwithstanding the foregoing, the term “Independent Counsel”
shall not include any person who, under the applicable standards of professional conduct
then prevailing, would have a conflict of interest in representing either the Company or
Indemnitee in an action to determine Indemnitee’s rights under this Agreement.




     (i) “Proceeding” includes any action, suit, arbitration, alternate dispute resolution
mechanism, investigation, administrative hearing or any other actual, threatened or
completed proceeding whether civil, criminal, administrative or investigative, other than
one initiated by Indemnitee. For purposes of the foregoing sentence, a “Proceeding” shall
not be deemed to have been initiated by Indemnitee where Indemnitee seeks pursuant to
Section 9 of this Agreement to enforce Indemnitee’s rights under this Agreement.



     2. Term of Agreement. This Agreement shall continue until and terminate upon the
later of: (a) 10 years after the date that Indemnitee has ceased to serve as a director, officer,
employee, agent or fiduciary of the Company or of any other corporation, partnership, joint
venture, trust, employee benefit plan or other enterprise which Indemnitee served at the express
written request of the Company or (b) the final termination of all pending Proceedings in respect
of which Indemnitee is granted rights of indemnification or advancement of expenses hereunder and
of any proceeding commenced by Indemnitee pursuant to Section 9 of this Agreement relating thereto.
In addition, no legal action shall be brought and no cause of action shall be asserted by or in
the right of the Company against Indemnitee, Indemnitee’s estate, spouse, heirs, executors or
personal or legal representatives after the expiration of five (5) years from the date of accrual
of such cause of action, and any claim or cause of action of the Company shall be extinguished and
deemed released unless asserted by the timely filing of a legal action within such five (5) year
period; provided, however, that if any shorter period of limitations is otherwise applicable to any
such cause of action, such shorter period shall govern.



     3. Services by Indemnitee, Notice of Proceedings.




     (a) Services. Indemnitee agrees to serve as a director of the Company.
Indemnitee may at any time and for any reason resign from such position (subject to any
other contractual obligation or any obligation imposed by operation of law).



Sucampo Pharmaceuticals, Inc.

Outside Director Indemnification Agreement




3









 






     (b) Notice of Proceeding. Indemnitee agrees promptly to notify the Company in
writing upon being served with any summons, citation, subpoena, complaint, indictment,
information or other document relating to any Proceeding or matter that may be subject to
indemnification or advancement of Expenses covered hereunder.



     4. Indemnification.




     (a) In General. In connection with any Proceeding, the Company shall indemnify
and advance Expenses to Indemnitee as provided in this Agreement and to the fullest extent
permitted by applicable law in effect on the date hereof and to such greater extent as
applicable law may thereafter from time to time permit.




     (b) Proceedings Other Than Proceedings by or in the Right of the Company.
Indemnitee shall be entitled to the rights of indemnification provided in this Section 4(b)
if, by reason of Indemnitee’s Corporate Status, Indemnitee is, or is threatened to be made,
a party to any Proceeding, other than a Proceeding by or in the right of the Company.
Indemnitee shall be indemnified against Expenses, judgments, penalties, fines and amounts
paid in settlements actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf
in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee
acted in Good Faith including without limitation, any and all losses, claims, damages,
expenses and liabilities, joint or several (including any investigation, legal and other
expenses incurred in connection with, and any amount paid in settlement of, any action,
suit, proceeding or any claim asserted) under the Securities Act of 1933, the Securities
Exchange Act of 1934, as amended (the “Exchange Act of 1934”) or other federal or state
statutory law or regulation, at common law or otherwise or which relate directly or
indirectly to the registration, purchase, sale or ownership of any securities of the Company
or to any fiduciary obligation owed with respect thereto or as a direct or indirect result
of any Proceeding or any claim, issue or matter therein made by any stockholder of the
Company against Indemnitee and arising out of or related to any round of financing of the
Company (including but not limited to Proceedings or any claims, issues or matters therein
regarding non-participation, or non-pro rata participation, in such round by such
stockholder), or made by a third party against Indemnitee based on any misstatement or
omission of a material fact by the Company in violation of any duty of disclosure imposed on
the Company by federal or state securities or common laws.




     (c) Proceedings by or in the Right of the Company. Indemnitee shall be
entitled to the rights of indemnification provided in this Section 4(c) if, by reason of
Indemnitee’s Corporate Status, Indemnitee is or is threatened to be made a party to any
Proceeding brought by or in the right of the Company to procure a judgment in its favor.
Indemnitee shall be indemnified against Expenses, judgments, penalties and amounts paid in
settlement, actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in
connection with such Proceeding if Indemnitee acted in Good Faith. Notwithstanding the
foregoing, no such indemnification shall be made in respect of any claim, issue or matter in
such Proceeding as to which Indemnitee shall have been adjudged, in a final, nonappealable
determination, to be liable to the Company if



Sucampo Pharmaceuticals, Inc.

Outside Director Indemnification Agreement




4









 






applicable law prohibits such indemnification; provided, however, that, if applicable
law so permits, indemnification shall nevertheless be made by the Company in such event if
and only to the extent that the Court of Chancery of the State of Delaware, or the court in
which such Proceeding shall have been brought or is pending, shall determine.




     (d) Indemnification of a Party Who is Wholly or Partly Successful.
Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by
reason of Indemnitee’s Corporate Status, a party to and is successful, on the merits or
otherwise, in any Proceeding, Indemnitee shall be indemnified to the maximum extent
permitted by law against all Expenses, judgments, penalties, fines and amounts paid in
settlement, actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in
connection therewith. If Indemnitee is not wholly successful in such Proceeding but is
successful, on the merits or otherwise, as to one or more but less than all claims, issues
or matters in such Proceeding, the Company shall indemnify Indemnitee to the maximum extent
permitted by law, against all Expenses, judgments, penalties, fines and amounts paid in
settlement, actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in
connection with each successfully resolved claim, issue or matter. For purposes of this
Section 4(d) and without limitation, the termination of any claim, issue or matter in such a
Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful
result as to such claim, issue or matter, so long as there has been no finding (either
adjudicated or pursuant to Section 6) that Indemnitee did not act in Good Faith.




     (e) Indemnification for Expenses of a Witness. Notwithstanding any other
provision of this Agreement, to the extent that Indemnitee is, by reason of Indemnitee’s
Corporate Status, a witness in any Proceeding, Indemnitee shall be indemnified against all
Expenses actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in
connection therewith.




     (f) Assumption of Defense and Settlement. Notwithstanding any other provision
of this Agreement, with respect to any such Proceeding as to which the Indemnitee gives
notice to the Company of the commencement thereof:




     (1) the Company will be entitled to participate therein at its own expense;




     (2) the Company, jointly with any other indemnifying party similarly notified,
shall be entitled to assume the defense thereof, with counsel satisfactory to the
Indemnitee. If the Company assumes the defense of the Indemnitee, it shall notify
the Indemnitee, and after the Indemnitee receives such notice, the Company shall not
be liable to the Indemnitee under this Agreement for any Expenses incurred by the
Indemnitee after the date such notice was received. The Indemnitee shall be
entitled to employ Indemnitee’s own counsel at Indemnitee’s own expense.
Nevertheless, the Company shall pay for Indemnitee’s own counsel if (1) the Company
agrees to do the same, (2) the Indemnitee shall have reasonably concluded that there
may be a conflict of interest between the Company and the Indemnitee regarding the
defense of such action, or (3) the



Sucampo Pharmaceuticals, Inc.

Outside Director Indemnification Agreement




5









 






Company shall not in fact have employed counsel promptly to assume the defense
of the Proceeding. The Company shall not be entitled to assume the defense of any
Proceeding brought by or on behalf of the Company or as to which the Indemnitee
shall have reasonably concluded that there may be a conflict of interest between the
Company and the Indemnitee regarding the defense of such Proceeding; and




     (3) the Company shall not be liable to the Indemnitee under this Agreement for
any amounts paid in settlement of any Proceeding unless the Company consents to such
settlement. The Company shall not settle any Proceeding in any manner that would
impose any penalty or limitation on the Indemnitee without the Indemnitee’s written
consent. Neither the Company nor the Indemnitee will unreasonably withhold or
condition their consent to any proposed settlement.




     (g) Contribution.




     (1) Notwithstanding any other provision of this Agreement, if the
indemnification provided for in this Section 4 for any reason is held by a court of
competent jurisdiction to be unavailable to Indemnitee in respect of any losses,
claims, damages, Expenses or liabilities referred to therein, then the Company, in
lieu of indemnifying Indemnitee thereunder, shall contribute to the amount paid or
payable by Indemnitee as a result of such losses, claims, damages, Expenses or
liabilities




     (A) in such proportion as is appropriate to reflect the relative
benefits received by the Company and Indemnitee; or




     (B) if the allocation provided by clause (A) above is not permitted by
applicable law, in such proportion as is appropriate to reflect not only the
relative benefits referred to in clause (A) above but also the relative
fault of the Company and Indemnitee in connection with the action or
inaction which resulted in such losses, claims, damages, Expenses or
liabilities, as well as any other relevant equitable considerations.




     (2) In connection with the registration of the Company’s securities, the
relative benefits received by the Company and Indemnitee shall be deemed to be in
the same respective proportions that the net proceeds from the offering (before
deducting expenses) received by the Company and Indemnitee, in each case as set
forth in the table on the cover page of the applicable prospectus, bear to the
aggregate public offering price of the securities so offered. The relative fault of
the Company and Indemnitee shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the omission or
alleged omission to state a material fact relates to information supplied by the
Company or Indemnitee and the parties’ relative intent, knowledge, access to
information and opportunity to correct or prevent such



Sucampo Pharmaceuticals, Inc.

Outside Director Indemnification Agreement




6









 






statement or omission. The Company and Indemnitee agree that it would not be
just and equitable if contribution pursuant to this Section 4(g) were determined by
pro rata or per capita allocation or by any other method of allocation which does
not take account of the equitable considerations referred to in the immediately
preceding paragraphs .




     (3) In connection with the registration of the Company’s securities, in no
event shall Indemnitee be required to contribute any amount under this Section 4(g)
in excess of the lesser of:




     (A) that proportion of the total of such losses, claims, damages,
Expenses or liabilities indemnified against equal to the proportion of the
total securities sold under such registration statement which is being sold
by Indemnitee; or




     (B) the proceeds received by Indemnitee from its sale of securities
under such registration statement.




     (4) Persons found guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act of 1933) shall only be entitled to contribution
from any person who was found guilty of such fraudulent misrepresentation.



     5. Exceptions



     Any other provision herein to the contrary notwithstanding, the Company shall not be obligated
pursuant to the terms of this Agreement:




     (a) Claims Under Section 16(b). To indemnify Indemnitee for expenses and the
payment of profits arising from the purchase and sale by Indemnitee of securities in
violation of Section 16(b) of the Exchange Act of 1934 or any similar successor statute; or




     (b) Unlawful Indemnification. To indemnify Indemnitee if a final,
nonappealable decision by a court having jurisdiction in the matter shall determine that
such indemnification is not lawful.



     6. Advancement of Expenses. Notwithstanding any provision to the contrary in Section
7, the Company shall advance all reasonable Expenses which, by reason of Indemnitee’s Corporate
Status, were incurred by or on behalf of Indemnitee in connection with any Proceeding, within 20
days after the receipt by the Company of a statement or statements from Indemnitee requesting such
advance or advances, whether prior to or after final disposition of such Proceeding. Such
statement or statements shall reasonably evidence the Expenses incurred by Indemnitee and shall be
preceded or accompanied by an undertaking by or on behalf of Indemnitee to repay any Expenses if it
shall ultimately be determined that Indemnitee is not entitled to be indemnified against such
Expenses. Any advance and undertakings to repay pursuant to this Section 6 shall be unsecured and
interest free.



Sucampo Pharmaceuticals, Inc.

Outside Director Indemnification Agreement




7









 





     7. Procedures for Determination of Entitlement to Indemnification.




     (a) Initial Request. To obtain indemnification under this Agreement,
Indemnitee shall submit to the Company a written request, including therein or therewith
such documentation and information as is reasonably available to Indemnitee and is
reasonably necessary to determine whether and to what extent Indemnitee is entitled to
indemnification. The Secretary of the Company shall promptly advise the Board in writing
that Indemnitee has requested indemnification.




     (b) Method of Determination. A determination (if required by applicable law)
with respect to Indemnitee’s entitlement to indemnification shall be made as follows:




     (1) if a Change in Control has occurred, unless Indemnitee shall request in
writing that such determination be made in accordance with clause (2) of this
Section 7(b), the determination shall be made by Independent Counsel in a written
opinion to the Board, a copy of which shall be delivered to Indemnitee;




     (2) if a Change of Control has not occurred, the determination shall be made by
the Board by a majority vote of Disinterested Directors, even though less than a
quorum. In the event that there are no Disinterested Directors or if such
Disinterested Directors so direct, the determination shall be made by Independent
Counsel in a written opinion to the Board, a copy of which shall be delivered to
Indemnitee.




     (c) Selection, Payment, Discharge, of Independent Counsel. In the event the
determination of entitlement to indemnification is to be made by Independent Counsel
pursuant to Section 7(b) of this Agreement, the Independent Counsel shall be selected, paid
and discharged in the following manner:




     (1) If a Change of Control has not occurred, the Independent Counsel shall be
selected by the Board, and the Company shall give written notice to Indemnitee
advising Indemnitee of the identity of the Independent Counsel so selected.




     (2) If a Change of Control has occurred, the Independent Counsel shall be
selected by Indemnitee (unless Indemnitee shall request that such selection be made
by the Board, in which event clause (1) of this Section 7(c) shall apply), and
Indemnitee shall give written notice to the Company advising it of the identity of
the Independent Counsel so selected.




     (3) Following the initial selection described in clauses (1) and (2) of this
Section 7(c), Indemnitee or the Company, as the case may be, may, within seven days
after such written notice of selection has been given, deliver to the other party a
written objection to such selection. Such objection may be asserted only on the
ground that the Independent Counsel so selected does not meet the requirements of
“Independent Counsel” as defined in this Agreement, and the objection shall set
forth with particularity the factual basis of such assertion.



Sucampo Pharmaceuticals, Inc.

Outside Director Indemnification Agreement




8









 






Absent a proper and timely objection, the person so selected shall act as
Independent Counsel. If such written objection is made, the Independent Counsel so
selected may not serve as Independent Counsel unless and until a court has
determined that such objection is without merit.




     (4) Either the Company or Indemnitee may petition any court of competent
jurisdiction if the parties have been unable to agree on the selection of
Independent Counsel within 20 days after submission by Indemnitee of a written
request for indemnification pursuant to Section 7(a) of this Agreement. Such
petition may request a determination whether an objection to the party’s selection
is without merit and/or seek the appointment as Independent Counsel of a person
selected by the Court or by such other person as the Court shall designate. A
person so appointed shall act as Independent Counsel under Section 7(b) of this
Agreement.




     (5) The Company shall pay any and all reasonable fees and expenses of
Independent Counsel incurred by such Independent Counsel in connection with acting
pursuant to this Agreement, and the Company shall pay all reasonable fees and
expenses incident to the procedures of this Section 7(c), regardless of the manner
in which such Independent Counsel was selected or appointed.




     (6) Upon the due commencement of any judicial proceeding or arbitration
pursuant to Section 9(c) of this Agreement, Independent Counsel shall be discharged
and relieved of any further responsibility in such capacity (subject to the
applicable standards of professional conduct then prevailing).




     (d) Cooperation. Indemnitee shall cooperate with the person, persons or entity
making the determination with respect to Indemnitee’s entitlement to indemnification under
this Agreement, including providing to such person, persons or entity upon reasonable
advance request any documentation or information which is not privileged or otherwise
protected from disclosure and which is reasonably available to Indemnitee and reasonably
necessary to such determination. Any costs or Expenses incurred by Indemnitee in so
cooperating with the person, persons or entity making such determination shall be borne by
the Company (irrespective of the determination as to Indemnitee’s entitlement to
indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless
therefrom.




     (e) Payment. If it is determined that Indemnitee is entitled to
indemnification, payment to Indemnitee shall be made within 10 days after such
determination.



     8. Presumptions and Effect of Certain Proceedings.




     (a) Burden of Proof. In making a determination with respect to entitlement to
Indemnification hereunder, the person or persons or entity making such determination shall
presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee
has submitted a request for indemnification in accordance with Section 7(a), and the Company
shall have the burden of proof to overcome that presumption in



Sucampo Pharmaceuticals, Inc.

Outside Director Indemnification Agreement




9









 






connection with the making by any person, persons or entity of any determination
contrary to that presumption.




     (b) Effect of Other Proceedings. The termination of any Proceeding or of any
claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea
of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in
this Agreement) of itself adversely affect the right of Indemnitee to indemnification or
create a presumption that Indemnitee did not act in Good Faith.




     (c) Reliance as Safe Harbor. For purposes of any determination of Good Faith,
Indemnitee shall be deemed to have acted in Good Faith if Indemnitee’s action is based on
the records or books of account of the Enterprise, including financial statements, or on
information supplied to Indemnitee by the officers of the Enterprise in the course of their
duties, or on the advice of legal counsel for the Enterprise or on information or records
given or reports made to the Enterprise by an independent certified public accountant or by
an appraiser or other expert selected with reasonable care by the Enterprise. The
provisions of this Section 8(c) shall not be deemed to be exclusive or to limit in any way
the other circumstances in which the Indemnitee may be deemed to have met the applicable
standard of conduct set forth in this Agreement.




     (d) Actions of Others. The knowledge and/or actions, or failure to act, of any
director, officer, agent or employee of the Enterprise shall not be imputed to Indemnitee
for purposes of determining the right to indemnification under this Agreement.



     9. Remedies of Indemnitee.




     (a) Application. This Section 9 shall apply in the event of a Dispute. For
purposes of this article, “Dispute” shall mean any of the following events:




     (1) a determination is made pursuant to Section 7 of this Agreement that
Indemnitee is not entitled to indemnification under this Agreement;




     (2) advancement of Expenses is not timely made pursuant to Section 6 of this
Agreement;




     (3) if the determination of entitlement to be made pursuant to Section 7(b) of
this Agreement is to be made by the Board and the Board has not made such
determination within 30 days after receipt by the Company of the request for
indemnification;




     (4) if the determination of entitlement to be made pursuant to Section 7(b) of
this Agreement is to be made by Independent Counsel and Independent Counsel has not
made such determination within 60 days after receipt by the Company of the request
for indemnification;



Sucampo Pharmaceuticals, Inc.

Outside Director Indemnification Agreement




10









 






     (5) payment of indemnification is not made pursuant to Section 4(e) of this
Agreement within 10 days after receipt by the Company of a written request therefor;
or




     (6) payment of indemnification is not made within 10 days after a determination
has been made that Indemnitee is entitled to indemnification or such determination
is deemed to have been made pursuant to Section 7 of this Agreement.




     (b) Adjudication. In the event of a Dispute, Indemnitee shall be entitled to
an adjudication in an appropriate court in the State of Delaware, or in any other court of
competent jurisdiction, of Indemnitee’s entitlement to such indemnification or advancement
of Expenses. Alternatively, Indemnitee, at Indemnitee’s option, may seek an award in
arbitration to be conducted by a single arbitrator pursuant to the rules of the American
Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication
or an award in arbitration within 180 days following the date on which Indemnitee first has
the right to commence such proceeding pursuant to this Section 9(b). The Company shall not
oppose Indemnitee’s right to seek any such adjudication or award in arbitration.




     (c) De Novo Review. In the event that a determination shall have been made
pursuant to Section 7 of this Agreement that Indemnitee is not entitled to indemnification,
any judicial proceeding or arbitration commenced pursuant to this Section 9 shall be
conducted in all respects as a de novo trial, or arbitration, on the merits, and Indemnitee
shall not be prejudiced by reason of that adverse determination. In any such proceeding or
arbitration, the Company shall have the burden of proving that Indemnitee is not entitled to
indemnification or advancement of Expenses, as the case may be.




     (d) Company Bound. If a determination shall have been made or deemed to have
been made pursuant to Section 7 of this Agreement that Indemnitee is entitled to
indemnification, the Company shall be bound by such determination in any judicial proceeding
or arbitration absent (i) a misstatement by Indemnitee of a material fact, or an omission of
a material fact necessary to make Indemnitee’s statement not materially misleading in
connection with the request for indemnification or (ii) a prohibition of such
indemnification under applicable law.




     (e) Procedures Valid. The Company shall be precluded from asserting in any
judicial proceeding or arbitration commenced pursuant to this Section 9 that the procedures
and presumptions of this Agreement are not valid, binding and enforceable and shall
stipulate in any such court or before any such arbitrator that the Company is bound by all
of the provisions of this Agreement.




     (f) Expenses of Adjudication. In the event that Indemnitee, pursuant to this
Section 9, seeks a judicial adjudication of or an award in arbitration to enforce
Indemnitee’s rights under, or to recover damages for breach of, this Agreement, Indemnitee
shall be entitled to recover from the Company, and shall be indemnified by the Company
against, any and all expenses (of the types described in the definition of



Sucampo Pharmaceuticals, Inc.

Outside Director Indemnification Agreement




11









 






Expenses in this Agreement) actually and reasonably incurred by Indemnitee in such
adjudication or arbitration, but only if Indemnitee prevails therein. If it shall be
determined in such adjudication or arbitration that Indemnitee is entitled to receive part
but not all of the indemnification or advancement of expenses sought, the expenses incurred
by Indemnitee in connection with such adjudication or arbitration shall be appropriately
prorated.



     10. Non-exclusivity, Insurance, Subrogation.




     (a) Non-Exclusivity. The rights of indemnification and to receive advancement
of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights
to which Indemnitee may at any time be entitled under applicable law, the Certificate of
Incorporation, the Bylaws, any agreement, a vote of stockholders or a resolution of
directors, or otherwise. No amendment, alteration, rescission or replacement of this
Agreement or any provision hereof shall be effective as to Indemnitee with respect to any
action taken or omitted by such Indemnitee in Indemnitee’s Corporate Status prior to such
amendment, alteration, rescission or replacement.




     (b) Insurance. The Company may maintain an insurance policy or policies
against liability arising out of this Agreement or otherwise.




     (c) Subrogation. In the event of any payment under this Agreement, the Company
shall be subrogated to the extent of such payment to all of the rights of recovery of
Indemnitee, who shall execute all papers required and take all action necessary to secure
such rights, including execution of such documents as are necessary to enable the Company to
bring suit to enforce such rights.




     (d) No Duplicative Payment. The Company shall not be liable under this
Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the
extent that Indemnitee has otherwise actually received such payment under any insurance
policy, contract, agreement or otherwise.



     11. Miscellaneous Provisions.




     (a) Entire Agreement. This Agreement contains the entire understanding between
the parties hereto with respect to the subject matter hereof and supersedes any prior
understandings, agreements or representations, written or oral, relating to the subject
matter hereof.




     (b) Counterparts. This Agreement may be executed in separate counterparts,
each of which will be an original and all of which taken together shall constitute one and
the same agreement, and any party hereto may execute this Agreement by signing any such
counterpart.




     (c) Severability. Whenever possible, each provision of this Agreement shall be
interpreted in such a manner as to be effective and valid under applicable law, but if any
provision of this Agreement is held to be invalid, illegal or unenforceable under any



Sucampo Pharmaceuticals, Inc.

Outside Director Indemnification Agreement




12









 






applicable law or rule, the validity, legality and enforceability of the other
provision of this Agreement will not be affected or impaired thereby.




     (d) Successors and Assigns. This Agreement shall be binding upon and inure to
the benefit of the parties hereto and their respective heirs, personal representatives and
successors and permitted assigns. The Company shall not assign any of its obligations
hereunder without the express prior written consent of the Indemnitee. For the avoidance of
doubt, a merger or consolidation of the Company with or into another entity shall not be
deemed an assignment hereunder if the surviving party to such transaction succeeds to the
obligations of this Agreement by operation of law. Notwithstanding anything herein to the
contrary, if any person or entity acquires all or substantially all of the business or
assets of the Company in a transaction approved by the Board, the Company may assign its
obligations hereunder to such person or entity without the consent of the Indemnitee.




     (e) Modification, Amendment, Waiver or Termination. No provision of this
Agreement may be modified, amended, waived or terminated except by an instrument in writing
signed by the parties to this Agreement. No course of dealing between the parties will
modify, amend, waive or terminate any provision of this Agreement or any rights or
obligations of any party under or by reason of this Agreement.




     (f) Notices. All notices, consents, requests, instructions, approvals or other
communications provided for herein shall be in writing and delivered by personal delivery,
overnight courier, mail, electronic facsimile or e-mail addressed to the receiving party at
the address set forth herein. All such communications shall be effective when received.


If to the Company:



Ryuji Ueno, M.D., Ph.D., Ph.D.

Chief Executive Officer, Chief Scientific Officer and

Chair of the Board of Directors

c/o Sucampo Pharmaceuticals, Inc.

4520 East-West Highway

Suite 300

Bethesda, MD 20814



If to the Indemnitee:




	 	 	 	 	 
	 
	 

	 	 

	 	 
	 
	 	 	 	 
	 

	 	 

	 	 
	 
	 	 	 	 
	 

	 	 

	 	 






     Any party may change the address set forth above by notice to each other party given as
provided herein.



Sucampo Pharmaceuticals, Inc.

Outside Director Indemnification Agreement




13









 






     (g) Headings. The headings and any table of contents contained in this
Agreement are for reference purposes only and shall not in any way affect the meaning or
interpretation of this Agreement.




     (h) Governing Law. ALL MATTERS RELATING TO THE INTERPRETATION, CONSTRUCTION,
VALIDITY AND ENFORCEMENT OF THIS AGREEMENT SHALL BE GOVERNED BY THE INTERNAL LAWS OF THE
STATE OF DELAWARE, WITHOUT GIVING EFFECT TO ANY CHOICE OF LAW PROVISIONS THEREOF.




     (i) Third-Party Benefit. Nothing in this Agreement, express or implied, is
intended to confer upon any other person any rights, remedies, obligations or liabilities of
any nature whatsoever.




     (j) Jurisdiction and Venue. THIS AGREEMENT MAY BE ENFORCED IN ANY FEDERAL
COURT OR STATE COURT SITTING IN DELAWARE, AND EACH PARTY CONSENTS TO THE JURISDICTION AND
VENUE OF ANY SUCH COURT AND WAIVES ANY ARGUMENT THAT VENUE IN SUCH FORUM IS NOT CONVENIENT.
IF ANY PARTY COMMENCES ANY ACTION UNDER ANY TORT OR CONTRACT THEORY ARISING DIRECTLY OR
INDIRECTLY FROM THE RELATIONSHIP CREATED BY THIS AGREEMENT IN ANOTHER JURISDICTION OR VENUE,
ANY OTHER PARTY TO THIS AGREEMENT SHALL HAVE THE OPTION OF TRANSFERRING THE CASE TO THE
ABOVE-DESCRIBED VENUE OR JURISDICTION OR, IF SUCH TRANSFER CANNOT BE ACCOMPLISHED, TO HAVE
SUCH CASE DISMISSED WITHOUT PREJUDICE.




     (k) Remedies. The parties agree that money damages may not be an adequate
remedy for any breach of the provisions of this Agreement and that any party may, in its
discretion, apply to any court of law or equity of competent jurisdiction for specific
performance and injunctive relief in order to enforce or prevent any violations this
Agreement, and any party against whom such proceeding is brought hereby waives the claim or
defense that such party has an adequate remedy at law and agrees not to raise the defense
that the other party has an adequate remedy at law.



[REMAINDER OF THIS PAGE LEFT INTENTIONALLY BLANK]




Sucampo Pharmaceuticals, Inc.

Outside Director Indemnification Agreement




14









 





          IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date set forth
in the first paragraph.



	 	 	 	 	 	 	 
	 	 	SUCAMPO PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	 	 	 
	 

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 
	 

	 	Name:	 	 	 	 
	 

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 
	 

	 	Its:	 	 	 	 
	 

	 	 	 	 

	 	 
	 
	 	 	 	 	 	 
	 	 	INDEMNITEE	 	 
	 
	 	 	 	 	 	 
	 
	 	 	 	 	 
	 	 	[Name of Indemnitee]
	 	 






Sucampo Pharmaceuticals, Inc.

Outside Director Indemnification Agreement




15